Cargando…

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine

BACKGROUND: Postmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements. The poor compliance may increase their potential of fractures and the prevalence of side effects. In this study, the compliance of osteoporotic women on bisphosphonate therapy to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radwan, Asma, Shraim, Naser, Elaraj, Josephean, Hamad, Anwar, Fatayer, Dana, Jarar, Bayan, Johar, Ayoub, Zriqah, Areen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991824/ https://www.ncbi.nlm.nih.gov/pubmed/35392893 http://dx.doi.org/10.1186/s12905-022-01690-5

Ejemplares similares

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy
por: Sewerynek, Ewa, et al.
Publicado: (2013)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
por: Catalano, Antonino, et al.
Publicado: (2021)

Screening of Antioxidant and Antimicrobial Activity of Micromeria fruticosa serpyllifolia Volatile Oils: A Comparative Study of Plants Collected from Different Regions of West Bank, Palestine
por: Salameh, Nihaya, et al.
Publicado: (2020)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
por: Calvo-Gallego, José L., et al.
Publicado: (2022)

Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study
por: Villagómez Vega, Alejandra, et al.
Publicado: (2023)

Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
por: Deng, Jing, et al.
Publicado: (2018)

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021)

Chemical Composition and Enzymatic Screening of Micromeria fruticosa serpyllifolia Volatile Oils Collected from Three Different Regions of West Bank, Palestine
por: Salameh, Nihaya, et al.
Publicado: (2018)

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
por: Mok, Ji Oh, et al.
Publicado: (2013)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
por: Iwamoto, Jun, et al.
Publicado: (2009)

Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2009)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
por: Khanizadeh, Fatemeh, et al.
Publicado: (2018)

The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis
por: Suh, Hee-Won, et al.
Publicado: (2012)

Thoracic surgery in Palestine
por: Idkedek, Mayar Ishaq, et al.
Publicado: (2022)

Chromatographic analysis of the chemical composition and anticancer activities of Curcuma longa extract cultivated in Palestine
por: Abualhasan, Murad, et al.
Publicado: (2023)

Treated Hypertension has No Influence on the Efficacy of Alendronate in the Therapy of Postmenopausal Osteoporosis: A Non-Randomized, Non-Blind, Controlled Prospective Study
por: Matziolis, Doerte, et al.
Publicado: (2011)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
por: Chen, Ling-Xiao, et al.
Publicado: (2015)

A critical review of brand and generic alendronate for the treatment of osteoporosis
por: Brown, Jacques P, et al.
Publicado: (2013)

Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women
por: Um, Mi Jung, et al.
Publicado: (2017)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Extemporaneous Compounding and Physiological Modeling of Amlodipine/Valsartan Suspension
por: Aabed, Wafa' J., et al.
Publicado: (2021)

The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women
por: Mobini, Maryam, et al.
Publicado: (2016)

Postmenopausal Osteoporosis
por: Kamel, Hosem K.
Publicado: (2006)

Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal Japanese women with osteoporosis: a clinical practice-based observational study
por: Iwamoto, Jun, et al.
Publicado: (2012)

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_okf4b9c88bnqaacelcipk8gcch